RecruitingNot ApplicableNCT05503875
Immunoclassification of Psoriasis: a Strategy for Precision Medicine
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment
100 participants
Start Date
Jan 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria1
- to 75 years of age 2.Moderate to severe chronic psoriasis, BSA≥3% 3.Duration of psoriasis≥6 months 4.Patients must be candidate for systemic therapy 5.Informed consent must be obtained 6.For female, ß-hCG test is negative and contraception is accepted
Exclusion Criteria5
- Having severe infections, including hepatitis, HIV and tuberculosis
- Having significant allergies to biological agents
- Having a history of malignancy
- Refusal of contraception
- Having serious or unstable/uncontrolled illnesses
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALadalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05503875
Related Trials
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT048648861 location
Regulation of Inflammatory Genes in Psoriasis
NCT031256551 location
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
NCT052707331 location
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
Multi-Center PAMPA Study
NCT050047275 locations